BLRX News and Press, BioLineRx Ltd. From 08/30/23

2023-08-30 12:58:05 ET BioLineRx Ltd. (BLRX) Q2 2023 Earnings Conference Call August 30, 2023 7:30 PM ET Company Participants John Lacey - Head of Investor Relations and Corporate Communications Phil Serlin - Chief Executive Officer Mali Zeevi - Chief Financial O...

2023-08-30 07:02:33 ET BioLineRx press release ( NASDAQ: BLRX ): Q2 GAAP EPS of -$0.02. As of June 30, 2023, the Company held cash, cash equivalents, and short-term bank deposits of $32.8 million and anticipates this will be sufficient to fund operations, as currently plan...

BioLineRx Reports Second Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates PR Newswire - On Track for September 9, 2023 PDUFA Target Action Date on NDA for Motixafortide in Stem Cell Mobilization (SCM) for Autologous Transplantation in Multiple Myel...

2023-08-22 09:27:19 ET Fulcrum Therapeutics ( FULC ) +36% as FDA lifts clinical hold on sickle-cell disease candidate . ProMIS Neurosciences ( PMN ) +30% on $20.4M private placement . Fabrinet ( FN ) +24% on Q4 earnings release . Hallmark Fi...

BioLineRx to Report Second Quarter 2023 Results on August 30, 2023 PR Newswire - Management to Hold Conference Call at 10:00 a.m. EDT - TEL AVIV, Israel , Aug. 22, 2023 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a pre-commercial stag...

2023-08-07 14:34:09 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips One of the safest sectors on the market is biotech. After all, we can’t stop people from aging — at least not yet. We have millions of people retiring and demanding better care. T...

BioLineRx Announces Initiation of Randomized Phase 2 Clinical Trial in First Line Metastatic Pancreatic Cancer Based on Preliminary Data from Single-Arm Pilot Phase; Combination Trial Includes Investigational Candidate Motixafortide PR Newswire TEL AVIV, Israel , Jul...

2023-07-10 19:36:22 ET Summary A PDUFA date of September 9, 2023 has been established for review of Motixafortide for Autologous Transplantation in Multiple Myeloma. Results from a phase 2 Columbia University investigator study, using Motixafortide in combination with LIBTAYO + SO...

2023-06-29 14:00:35 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Now is a great time to accumulate top undervalued biotech stocks . For one, the sector is recession-proof. That’s because we can’t stop people from aging, or from seeking ...

2023-05-25 18:21:14 ET If you’re like many retail traders in the stock market today, penny stocks are a popular prospect. This article looks at some of the most active penny stocks today with late-breaking momentum. They could also be on the radar of traders before next week. But...